{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:41:35Z","timestamp":1791312095729,"version":"4.3.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.urolonc.2016.04.004","type":"journal-article","created":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T17:29:29Z","timestamp":1463074169000},"page":"416.e1-416.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Development and external multicenter validation of Chinese Prostate Cancer Consortium prostate cancer risk calculator for initial prostate biopsy"],"prefix":"10.1016","volume":"34","author":[{"given":"Rui","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangqun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shancheng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fubo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanliang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2016.04.004_bib1","series-title":"GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]","author":"Ferlay","year":"2013"},{"key":"10.1016\/j.urolonc.2016.04.004_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajur.2014.08.007","article-title":"Prostate cancer in Asia: a collaborative report","volume":"1","author":"Rui","year":"2014","journal-title":"Asian J Urol"},{"key":"10.1016\/j.urolonc.2016.04.004_bib3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.eururo.2009.08.025","article-title":"A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer","volume":"57","author":"Roobol","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.04.004_bib4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/jnci\/djj131","article-title":"Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial","volume":"98","author":"Thompson","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2016.04.004_bib5","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1158\/1078-0432.CCR-10-1328","article-title":"The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group","volume":"16","author":"Vickers","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2016.04.004_bib6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ajur.2015.08.003","article-title":"Contemporary outcomes in the detection of prostate cancer using transrectal ultrasound-guided 12-core biopsy in Singaporean men with elevated prostate specific antigen and\/or abnormal digital rectal examination","volume":"2","author":"Lee","year":"2015","journal-title":"Asian J Urol"},{"key":"10.1016\/j.urolonc.2016.04.004_bib7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1442-2042.2005.01058.x","article-title":"Efficacy and morbidity of transrectal ultrasound-guided 12-core biopsy for detection of prostate cancer in Japanese men","volume":"12","author":"Matsumoto","year":"2005","journal-title":"IntJ Urol"},{"key":"10.1016\/j.urolonc.2016.04.004_bib8","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.urology.2007.07.052","article-title":". Detection rate of prostate cancer according to prostate-specific antigen and digital rectal examination in Korean men: a nationwide multicenter study","volume":"70","author":"Seo","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2016.04.004_bib9","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.4103\/1008-682X.150846","article-title":"Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0ng\/ml","volume":"17","author":"Rui","year":"2015","journal-title":"Asian J Androl"},{"key":"10.1016\/j.urolonc.2016.04.004_bib10","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/aja.2012.28","article-title":"External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer risk calculators in a Chinese cohort","volume":"14","author":"Zhu","year":"2012","journal-title":"Asian J Androl"},{"key":"10.1016\/j.urolonc.2016.04.004_bib11","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/pros.21475","article-title":"Can the prostate risk calculator based on Western population be applied to Asian population?","volume":"72","author":"Yoon","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2016.04.004_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00345-011-0804-y","article-title":"Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group","volume":"30","author":"Roobol","year":"2012","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2016.04.004_bib13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.juro.2012.12.108","article-title":"The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator","volume":"190","author":"Ankerst","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.04.004_bib14","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.eururo.2006.08.039","article-title":"Development and external validation of an extended 10-core biopsy nomogram","volume":"52","author":"Chun","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.04.004_bib15","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.eururo.2014.08.011","article-title":"The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men","volume":"66","author":"Vedder","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.04.004_bib16","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.2010.32.6371","article-title":"Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators","volume":"29","author":"Nam","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.04.004_bib17","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.urology.2014.02.035","article-title":"Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer","volume":"83","author":"Ankerst","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2016.04.004_bib18","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/aja.2013.100","article-title":"Chinese nomogram to predict probability of positive initial prostate biopsy: a study in Taiwan region","volume":"15","author":"Kuo","year":"2013","journal-title":"Asian J Androl"},{"key":"10.1016\/j.urolonc.2016.04.004_bib19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/aja.2012.111","article-title":"A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer","volume":"15","author":"Tang","year":"2013","journal-title":"Asian J Androl"},{"key":"10.1016\/j.urolonc.2016.04.004_bib20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/modpathol.3800054","article-title":"Gleason grading and prognostic factors in carcinoma of the prostate","volume":"17","author":"Humphrey","year":"2004","journal-title":"Mod Pathol"},{"key":"10.1016\/j.urolonc.2016.04.004_bib21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1097-0045(199610)29:4<231::AID-PROS4>3.0.CO;2-E","article-title":"Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients","volume":"29","author":"Carraro","year":"1996","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2016.04.004_bib22","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis Making"},{"key":"10.1016\/j.urolonc.2016.04.004_bib23","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/jjco\/28.11.666","article-title":"Results of transrectal ultrasound-guided biopsies and clinical significance of Japanese prostate cancer","volume":"28","author":"Egawa","year":"1998","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.04.004_bib24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00345-012-0869-2","article-title":"Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group","volume":"32","author":"Ankerst","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2016.04.004_bib25","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3349\/ymj.2013.54.3.665","article-title":"Can Western based online prostate cancer risk calculators be used to predict prostate cancer after prostate biopsy for the Korean population?","volume":"54","author":"Lee","year":"2013","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.urolonc.2016.04.004_bib26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.7863\/jum.2011.30.4.503","article-title":"Evaluating possible predictors of prostate cancer to establish a scoring system for repeat biopsies in Chinese men","volume":"30","author":"Xu","year":"2011","journal-title":"J Ultrasound Med"},{"key":"10.1016\/j.urolonc.2016.04.004_bib27","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.eururo.2008.01.017","article-title":"Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy","volume":"54","author":"Kawakami","year":"2008","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143916300126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143916300126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:08:05Z","timestamp":1761041285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143916300126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1078143916300126"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.04.004","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and external multicenter validation of Chinese Prostate Cancer Consortium prostate cancer risk calculator for initial prostate biopsy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}